Endomorphin-1, an endogenous mu-opioid receptor agonist, improves apomorphine-induced impairment of prepulse inhibition in mice.
The present study was designed to examine the effects of the endogenous mu-opioid receptor agonist endomorphin-1 on prepulse inhibition (PPI) in mice. Although apomorphine (1mg/kg) produced a marked decrease in PPI, endomorphin-1 (17.5 microg) had no marked effects on PPI or startle amplitude in normal mice. Endomorphin-1 (17.5 microg) inhibited the apomorphine (1mg/kg)-induced decrease in PPI. beta-Funaltrexamine (5 microg), a mu-opioid receptor antagonist, did not significantly antagonize the effects of endomorphin-1 (17.5 microg). Naloxonazine (35 mg/kg), a mu(1)-opioid receptor antagonist, antagonized the effects of endomorphin-1 (17.5 microg) on the apomorphine (1mg/kg)-induced decrease in PPI, whereas naloxonazine (35 mg/kg) itself was without significant effects on the apomorphine (1mg/kg)-induced decrease. These results suggest that endomorphin-1 alleviates the impairment of PPI resulting from the hyperactivity of dopaminergic neurotransmission through the mediation of mu(1)-opioid receptors.